Investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) are being urged to take immediate action as the deadline to seek lead plaintiff status in a securities class action lawsuit approaches. The law firm Faruqi & Faruqi, LLP has issued a reminder that April 6, 2026, is the final date for affected investors to participate in this legal opportunity.

Understanding the Class Action Lawsuit

This securities class action lawsuit centers around allegations of significant violations of federal securities laws by Ultragenyx Pharmaceutical during a defined class period. Investors who acquired shares of Ultragenyx between March 24, 2020, and June 15, 2021, are specifically targeted in this notice, as they may have experienced financial losses linked to the company’s alleged misrepresentations.

Key Allegations Against Ultragenyx

The lawsuit alleges that Ultragenyx engaged in misleading practices that inflated the value of its stock price. Key accusations include:

• Providing false and misleading statements regarding the efficacy and safety of its drug candidates.
• Failing to disclose adverse events associated with its treatments.
• Misrepresenting the company’s financial health and market position.

As a result of these allegations, investors may have suffered substantial financial losses when the truth regarding the company’s operations and prospects was revealed.

The Importance of Acting Quickly

The reminder from Faruqi & Faruqi emphasizes the urgency for investors to act promptly. To become a lead plaintiff, investors must file their motions by the April 6 deadline. The lead plaintiff plays a crucial role in representing the interests of all class members and can help shape the direction of the litigation.

Faruqi & Faruqi encourages all affected investors to contact their firm to discuss their potential claims and to receive guidance on how to proceed. The firm specializes in securities class action lawsuits and has a track record of successfully advocating for investors’ rights.

Who Can File a Claim?

To qualify as a lead plaintiff in this class action, investors must meet certain criteria:

• They must have purchased shares of Ultragenyx during the class period.
• They must have suffered losses as a result of the alleged misconduct.
• They should be willing to take an active role in the litigation process.

Potential plaintiffs are advised to gather documentation of their transactions, including purchase and sale records, to support their claims.

Steps to Take if You Are Affected

If you believe you have been negatively impacted by Ultragenyx’s alleged misconduct, consider following these steps:

1. Contact an Attorney: Reach out to a law firm experienced in securities class actions, like Faruqi & Faruqi, to discuss your situation.
2. Gather Evidence: Collect all relevant documentation regarding your investment in Ultragenyx, including transaction records and communications.
3. File Your Motion: Ensure that you file your motion for lead plaintiff status before the deadline.

By taking these steps, investors can position themselves to potentially recover losses incurred during the class period.

Conclusion

The upcoming April 6, 2026, deadline for Ultragenyx Pharmaceutical investors represents a critical window for action. Those who believe they have suffered losses due to the company’s alleged securities violations should not delay in seeking legal advice and taking steps towards participating in this class action lawsuit. With the support of experienced legal counsel, investors can better navigate the complexities of securities litigation and work towards reclaiming their financial losses.

For more information, affected investors can visit the Faruqi & Faruqi, LLP website or contact the firm directly to discuss their individual cases and the opportunity to join this class action.